WO2001046697A3 - Identification, assessment, prevention, and therapy of breast cancer - Google Patents

Identification, assessment, prevention, and therapy of breast cancer Download PDF

Info

Publication number
WO2001046697A3
WO2001046697A3 PCT/US2000/035214 US0035214W WO0146697A3 WO 2001046697 A3 WO2001046697 A3 WO 2001046697A3 US 0035214 W US0035214 W US 0035214W WO 0146697 A3 WO0146697 A3 WO 0146697A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
assessment
therapy
prevention
identification
Prior art date
Application number
PCT/US2000/035214
Other languages
French (fr)
Other versions
WO2001046697A2 (en
Inventor
James Lillie
Adam Palermo
Youzhen Wang
Kathleen Steinmann
Josh Elias
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Priority to AU25969/01A priority Critical patent/AU2596901A/en
Publication of WO2001046697A2 publication Critical patent/WO2001046697A2/en
Publication of WO2001046697A3 publication Critical patent/WO2001046697A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compositions, kits and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
PCT/US2000/035214 1999-12-21 2000-12-21 Identification, assessment, prevention, and therapy of breast cancer WO2001046697A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25969/01A AU2596901A (en) 1999-12-21 2000-12-21 Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US17140699P 1999-12-21 1999-12-21
US60/171,406 1999-12-21
US17642300P 2000-01-14 2000-01-14
US60/176,423 2000-01-14
US19047100P 2000-03-17 2000-03-17
US60/190,471 2000-03-17
US19348200P 2000-03-29 2000-03-29
US60/193,482 2000-03-29
US20523100P 2000-05-15 2000-05-15
US60/205,231 2000-05-15
US21323600P 2000-06-20 2000-06-20
US60/213,236 2000-06-20
US21986500P 2000-07-20 2000-07-20
US60/219,865 2000-07-20

Publications (2)

Publication Number Publication Date
WO2001046697A2 WO2001046697A2 (en) 2001-06-28
WO2001046697A3 true WO2001046697A3 (en) 2002-01-10

Family

ID=27569123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035214 WO2001046697A2 (en) 1999-12-21 2000-12-21 Identification, assessment, prevention, and therapy of breast cancer

Country Status (2)

Country Link
AU (1) AU2596901A (en)
WO (1) WO2001046697A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
JP2005500832A (en) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド Diagnosis and prognosis of breast cancer patients
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
AT410945B (en) * 2001-06-27 2003-08-25 Burkhard Dr Jansen Diagnosis of multiple sclerosis or tumors, by detecting absence of wild-type stem cell factor-apoptosis response gene, or the derived protein, also new nucleic acids
WO2003087154A2 (en) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
WO2003087122A2 (en) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
AU2005227598B2 (en) 2004-03-31 2011-01-20 Hiroyuki Aburatani Cancer diagnosis and treatment using anti-ROBO1 antibody
MX2008002101A (en) 2005-08-12 2008-04-19 Schering Corp Mcp1 fusions.
JP5117765B2 (en) 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775620A (en) * 1984-01-06 1988-10-04 The Regents Of The University Of California Cytokeratin tumor markers and assays for their detection
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
WO1997046884A1 (en) * 1996-06-05 1997-12-11 Matritech, Inc. Materials and methods for detection of breast cancer
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
WO1998035229A1 (en) * 1997-02-07 1998-08-13 Macquarie Research Ltd. Diagnosis of disease using tears
WO1999032625A2 (en) * 1997-12-19 1999-07-01 The University Of Michigan Nucleotide and protein sequence of mammastatin and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775620A (en) * 1984-01-06 1988-10-04 The Regents Of The University Of California Cytokeratin tumor markers and assays for their detection
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
WO1997046884A1 (en) * 1996-06-05 1997-12-11 Matritech, Inc. Materials and methods for detection of breast cancer
WO1998035229A1 (en) * 1997-02-07 1998-08-13 Macquarie Research Ltd. Diagnosis of disease using tears
WO1999032625A2 (en) * 1997-12-19 1999-07-01 The University Of Michigan Nucleotide and protein sequence of mammastatin and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERNARDINI ET AL: "Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor", EUROPEAN JOURNAL OF IMMUNOLOGY,DE,WEINHEIM, vol. 28, no. 2, 1 February 1998 (1998-02-01), pages 582 - 588, XP002092743, ISSN: 0014-2980 *
BERNSTEIN S H ET AL: "A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein -1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.", BRITISH JOURNAL OF HAEMATOLOGY, (1997 DEC) 99 (4) 888-95., XP001011409 *
DATABASE SWISS-PROT 1 January 1990 (1990-01-01), XP002171087 *
TANAKA, YOSHIYA (1) ET AL: "Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells.", CANCER RESEARCH, (SEPT. 15, 1998) VOL. 58, NO. 18, PP. 4138-4145., XP001010064 *
TEDLA N ET AL: "Abundant expresssion of chemokines in malignant and infective human lymphadenopathies", CYTOKINE,ACADEMIC PRESS LTD, PHILADELPHIA, PA,US, vol. 11, no. 7, July 1999 (1999-07-01), pages 531 - 540, XP002166395, ISSN: 1043-4666 *
WANG J M ET AL: "Chemokines and their role in tumor growth and metastasis", JOURNAL OF IMMUNOLOGICAL METHODS,NL,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, vol. 220, no. 1-2, 1 November 1998 (1998-11-01), pages 1 - 17, XP004144097, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
WO2001046697A2 (en) 2001-06-28
AU2596901A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001053836A3 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
WO2001018542A3 (en) Identification, assessment, prevention, and therapy of ovarian cancer
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2005118869A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
AU2002324451A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2005032328A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
WO2002044418A3 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2001079556A3 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001275346A1 (en) Compositions, kits, and methods for identification and modulation of type i diabetes
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2002044360A3 (en) Modified arginine deiminase
EP1117439A4 (en) Methods for identification, diagnosis, and treatment of breast cancer
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP